Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Pluri Inc.
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Pluri Inc.
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Pluri Inc.
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
$
PLUR
Pluri Inc.
CIK:
0001158780
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]
Revenues
$ 1,016
$ 1,336
Cost of revenues
(563)
(682)
Gross profit
453
654
Operating expenses:
Research and development expenses
(15,306)
(14,004)
Less: participation by the NIAID, the IIA (each, as defined below) and Horizon Europe
214
1,153
Research and development expenses, net
(15,092)
(12,851)
General and administrative expenses
(10,299)
(9,979)
Operating loss
(24,938)
(22,176)
Other financial income (expenses), net
476
(206)
Interest expense
(932)
(873)
Total financial income (expenses), net
(456)
(1,079)
Loss before taxes
(25,394)
(23,255)
Tax benefit
25
5
Net loss
(25,369)
(23,250)
Net loss attributed to non-controlling interests
(1,548)
(667)
Net loss attributed to shareholders
$ (23,821)
$ (22,583)
Loss per share:
Basic loss per share (in Dollars per share)
$ (2.44)
$ (3.56)
Diluted loss per share (in Dollars per share)
$ (2.44)
$ (3.56)
Weighted average number of shares used in computing basic loss per share (in Shares)
9,743,913
6,336,993
Weighted average number of shares used in computing diluted loss per share (in Shares)
9,743,913
6,336,993
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$ (25,369)
$ (23,250)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization
511
316
Loss on property and equipment
13
Share-based compensation to employees, directors and non-employee consultants
3,726
2,143
Increase in fair value of simple agreement for future equity, or SAFE, liability
80
Decrease in fair value of warrant and pre-funded warrant liability
(556)
Decrease (increase) in customer receivable, net
149
(202)
Decrease (increase) in prepaid expenses, other current assets and other long-term assets
(47)
1
Decrease in trade payables
(77)
(235)
Increase in other accounts payable, accrued vacation and recuperation, deferred tax liabilities and accrued expenses
124
377
Increase (decrease) in advances from customers
(80)
105
Increase in operating lease right-of-use asset and liability, net
1,458
834
Decrease in interest receivable on short-term deposits and restricted bank deposits
27
91
Effect of exchange rate changes on cash, cash equivalents, deposits, restricted cash and restricted bank deposits
(128)
(1,055)
Increase in short-term interest payable and exchange rate differences related to the EIB loan, net
142
3,262
Decrease in accrued severance pay, net
(117)
(42)
Net cash used for operating activities
(19,588)
(18,211)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment
(633)
(1,618)
Proceeds from sale of property and equipment
18
Proceeds from short-term deposits, net
10,518
9,271
Cash related to the Kokomodo Transaction (defined below)
373
Net cash provided by investing activities
9,903
8,026
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common shares, pre-funded warrants and warrants, net of issuance costs
5,074
9,580
Proceeds from the advance towards share subscription
1,250
Issuance costs related to issuance of shares in the Kokomodo Transaction (defined below)
(47)
Proceeds from SAFE
714
Net cash provided by financing activities
7,038
9,533
EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
27
177
Decrease in cash, cash equivalents, restricted cash and restricted bank deposits
(2,620)
(475)
Cash, cash equivalents, restricted cash and restricted bank deposits at the beginning of the period
7,196
7,671
Cash, cash equivalents, restricted cash and restricted bank deposits at the end of the period
4,576
7,196
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents
3,529
5,895
Restricted cash
29
422
Long-term restricted bank deposits
1,018
879
Total cash, cash equivalents, restricted cash and restricted bank deposits
4,576
7,196
(a) Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit
3
90
The Kokomodo Transaction (defined below)
4,686
Lease liabilities arising from obtaining right-of-use assets
$ 250
$ 1,080
v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Jun. 30, 2025
CURRENT ASSETS:
Cash and cash equivalents
$ 3,529
$ 5,895
Short-term bank deposits
4,275
14,718
Restricted cash
29
422
Customer receivables, net
87
236
Prepaid expenses and other current assets
810
824
Total current assets
8,730
22,095
LONG-TERM ASSETS:
Restricted bank deposits
1,018
879
Severance pay fund
702
610
Property and equipment, net
1,566
1,823
Advances for property and equipment
861
420
Intangible assets, net
2,613
2,793
Goodwill
3,136
3,136
Operating lease right-of-use asset
6,164
6,900
Other long-term assets
88
27
Total long-term assets
16,148
16,588
Total assets
24,878
38,683
CURRENT LIABILITIES
Trade payables
702
866
Accrued expenses
928
1,178
Operating lease liability
996
659
Accrued vacation and recuperation
911
859
Advances from customers
68
148
Loan from the European Investment Bank, or EIB
27,431
27,289
Other accounts payable
1,683
1,329
Total current liabilities
32,719
32,328
LONG-TERM LIABILITIES
Accrued severance pay
678
703
Operating lease liability
6,487
6,102
Deferred tax liabilities
384
415
Simple Agreement for Future Equity, or SAFE
794
Advance towards share subscription
1,250
Total long-term liabilities
9,593
7,220
COMMITMENTS AND CONTINGENCIES
Share capital:
Common shares, $0.00001 par value per share: authorized: 37,500,000 as of June 30, 2026 and 2025; issued and outstanding: 10,824,311 and 7,893,767 shares as of June 30, 2026 and 2025, respectively
[1]
Additional paid-in capital
443,840
436,213
Accumulated deficit
(466,876)
(443,055)
Total shareholders’ deficit
(23,036)
(6,842)
Non-controlling interests
5,602
5,977
Total deficit
(17,434)
(865)
Total liabilities and deficit
$ 24,878
$ 38,683
[1]
Less than $1